ArticleCancer research communications2026
Transcriptome-Based Synthetic Lethality Predictions to Improve Targeted Therapy/Immunotherapy Treatment Prioritization in Nonmetastatic Breast Cancer: BC-SELECT.
Article in Cancer research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Update of
Authors and funding
4 authors.
Funding
Abstract
Patients with nonmetastatic triple-negative breast cancer (TNBC) or HER2+ breast cancer do not currently have tools to predict treatment response or prioritize options prior to therapy initiation. Pathologic complete response (pCR) is a proxy that requires neoadjuvant treatment. BC-SELECT leverages genetic interactions [e.g., synthetic lethality (SL)/synthetic rescue (SR)] to predict treatment response via pCR from breast cancer gene expression data. BC-SELECT involves (i) "Training: gene-pair identification" that identifies clinically relevant partner genes from large-scale datasets for a given targeted therapy or immunotherapy target and (ii) "Training: parameter tuning" using clinical trials to predict treatment response. We evaluated BC-SELECT's ability to predict pCR for trastuzumab, poly (ADP-ribose) polymerase (PARP) inhibitors, and immunotherapy, with tuning supported by three trials (n = 86) and validation on nine unseen trials (n = 722). BC-SELECT significantly predicted pCR in 6 of 9 trials, including all PARP inhibitors [ROC-AUCs, 0.6-0.8; odds ratio (OR), 1.9-3.5] and immunotherapy (ROC-AUCs, 0.7-0.8; OR, 3.2-7.1). BC-SELECT significantly distinguished between pCR and residual disease in 8 of 9 trials. No current standard-of-care, pretreatment approaches predict benefit in nonmetastatic TNBC and HER2+ breast cancer. BC-SELECT leverages genetic interactions to predict treatment response from gene expression data. Our findings support development of BC-SELECT toward studying how to prioritize PARP inhibitors and immunotherapy in nonmetastatic breast cancer. SIGNIFICANCE: BC-SELECT is an algorithm that uses gene expression to predict pCR in breast cancer using targeted therapy and immunotherapy. BC-SELECT predicted response to PARP inhibitors and immunotherapy, distinguished responders and nonresponders, and identified different response patterns among tumors with low BRCA1/2 gene expression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.